Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 379Neoplasms 336Carcinoma, Non-Small-Cell Lung 297Prostatic Neoplasms 250Colorectal Neoplasms 223Lung Neoplasms 195Multiple Myeloma 155Ovarian Neoplasms 142Pancreatic Neoplasms 140Neoplasm Metastasis 132Leukemia, Myeloid, Acute 129Melanoma 112Squamous Cell Carcinoma of Head and Neck 96Lymphoma 89Carcinoma, Renal Cell 89Stomach Neoplasms 87Recurrence 87Lymphoma, Non-Hodgkin 86Endometrial Neoplasms 85Brain Neoplasms 83Carcinoma, Hepatocellular 82Precursor Cell Lymphoblastic Leukemia-Lymphoma 81Head and Neck Neoplasms 73Glioma 73Glioblastoma 73Uterine Cervical Neoplasms 71Sarcoma 69Urinary Bladder Neoplasms 67Hematologic Neoplasms 66Leukemia, Lymphocytic, Chronic, B-Cell 65

Interventions

darolutamide 1Rifampin 1Itraconazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Refractory or Relapsed Solid Tumors × 30 days × Clear all
NCT07620041 2026-06-02

QLC5508 in Advanced Solid Tumors:: C-QTc, Pharmacokinetics (PK) Comparisons and Drug-drug Interaction

Qilu Pharmaceutical Co., Ltd.

Phase 1 Not yet recruiting
48 enrolled
Other solid neoplasm

Refractory or Relapsed Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡